Both in Biotechnology
enGene Therapeutics vs Armata Pharmaceuticals
Over the past year ENGN returned −73.7% and ARMP returned −35.1%; their daily moves had a correlation of 0.05.
ENGN −73.7% ARMP −35.1%Growth of $1, one year, split-adjusted
| Metric | ENGN | ARMP |
|---|---|---|
| Price | $1.72 | $3.14 |
| Market cap | $115.3M | $116.8M |
| Today | +6.17% | +1.62% |
| 1 month | −4.4% | −18.4% |
| 6 months | −80.6% | −65.3% |
| Year to date | −81.0% | −50.0% |
| 1 year | −75.1% | −35.0% |
| Revenue growth (YoY) | — | +15.7% |
| Gross margin | — | 100.0% |
| Net margin | — | 2953.8% |
| P/E (TTM) | — | — |
| Price / sales | — | 21.1× |
| Net cash | $241.0M | -$259.6M |
| Dividend yield | — | — |
| Volatility (60d) | 58.2% | 114.9% |
| Short % of float | 3.4% | 4.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).